Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 470

Similar articles for PubMed (Select 17897298)

1.

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.

Br J Haematol. 2007 Oct;139(2):224-33.

PMID:
17897298
2.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.

PMID:
15566357
3.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

4.

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.

5.

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.

N Engl J Med. 2007 Sep 13;357(11):1083-93.

6.

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.

Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.

Haematologica. 2006 Dec;91(12):1635-43.

7.

Managing systemic light-chain amyloidosis.

Comenzo RL.

J Natl Compr Canc Netw. 2007 Feb;5(2):179-87. Review.

PMID:
17335687
8.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

9.

Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.

Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.

Ann Hematol. 2009 Jul;88(7):681-5. doi: 10.1007/s00277-008-0652-z. Epub 2008 Dec 6.

PMID:
19066891
10.

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M.

Blood. 1996 Oct 1;88(7):2801-6.

11.

Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.

Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.

Wien Klin Wochenschr. 2006 Feb;118(1-2):49-53.

PMID:
16489526
13.

Primary systemic amyloidosis.

Comenzo RL.

Curr Treat Options Oncol. 2000 Apr;1(1):83-9. Review.

PMID:
12057064
14.

Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.

Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.

Am J Kidney Dis. 2005 Aug;46(2):270-7. Review.

PMID:
16112045
15.

Autologous stem cell transplantation for primary systemic amyloidosis.

Comenzo RL, Gertz MA.

Blood. 2002 Jun 15;99(12):4276-82. Review.

16.

Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.

Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.

Bone Marrow Transplant. 2007 Sep;40(6):557-62. Epub 2007 Jun 25. Erratum in: Bone Marrow Transplant. 2007 Sep;40(6):607.

PMID:
17589534
17.

Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.

Schonland SO, Perz JB, Hundemer M, Hegenbart U, Kristen AV, Hund E, Dengler TJ, Beimler J, Zeier M, Singer R, Linke RP, Ho AD, Goldschmidt H.

Transplantation. 2005 Sep 27;80(1 Suppl):S160-3.

PMID:
16286897
18.

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.

PMID:
14734330
19.

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD.

Blood. 2007 Jan 15;109(2):457-64. Epub 2006 Sep 21.

20.

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA.

J Heart Lung Transplant. 2008 Aug;27(8):823-9. doi: 10.1016/j.healun.2008.05.016. Epub 2008 Jul 3.

PMID:
18656793
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk